Projet Archade
  • Europe en Basse Normandie
  • Europe
  • Conseil régional Basse-Normandie
  • IBA

News

Pr Habrand joins ARCHADE

Nov 2011

Pr Habrand joins ARCHADE

ARCHADE / Caen: Pr Jean-Louis HABRAND, from CRLCC François Baclesse (Caen) has been involved in the developments of hadrontherapy in France since the origin: in the middle of the 80’s…

Investments for the future

Apr 2011

Investments for the future

Successful candidate of the call for proposals initiated by Equipex, REC HADRON will acquire essential equipments for ARCHADE’s scientific researches

SAPHYN and IBA, partners for ARCHADE

Dec 2010

SAPHYN and IBA, partners for ARCHADE

A crucial stage in the implementation of the project.

ARCHADE seen from the United States

Dec 2010

ARCHADE seen from the United States

ARCHADE was presented to ionizing radiation specialists at the latest IBIBAM workshop, at Berkeley, in October 2010.

Summit meeting

Dec 2010

Marie-Hélène Moscatello, physicienne spécialiste des accélérateurs et Alejandro Mazal, chef de l’unité de physique médicale de l’Institut Curie, avec (au centre), le Professeur Hirohiko Tsujii, directeur de l’institut national des sciences radiologiques de Tokyo (NIRS).

ARCHADE was represented at the PTCOG (Particle Therapy Co-Operative Group), the major international radiotherapy event.


News in brief

IBA consulting industry in the Basse Normandie Region

Building: final proposals in March 2011

ARCHADE radiates throughout the Grand Ouest Region of France

Home

Each year in France, 350,000 new cases of cancer are diagnosed*.

Only about half of these can be cured with the therapeutic arsenal now at our disposal, namely surgery, chemotherapy and radiotherapy.

In this situation, the advent of a new form of radiotherapy, known as ‘hadrontherapy’, represents a fresh opening. Initial clinical trials have shown some promising results, especially in the case of cancers that today remain incurable or inoperable.

Before this innovative method of treatment can be extended, however, we still have some questions to answer: which tumours and which patients is this treatment suitable for? And under what conditions are they implemented?

The ARCHADE European Hadrontherapy Research Centre has been set up with this in mind. It will be the first centre in the world devoted exclusively to research in this field.

Project ARCHADE is an integral part of cancer treatment, for to understand hadrontherapy today is to be able to improve the cancer treatment of tomorrow.

* Source: Institut National de Veille Sanitaire, 2010.